ALDH7A1 and pulmonary arterial hypertension: Two of the three in the present study tested PDE inhibitors are in clinical use to treat primary pulmonary hypertension/erectile dysfunction (Sildenafil) [7,20] or multiple sclerosis or asthma (Ibudilast) [21].